REGULATORY

Japan OKs Listing of Evenity, Tarlige, Epclusa, and More on Feb. 26

February 20, 2019
The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, on February 20 approved a dozen new drugs for their NHI price listing on February 26, including Amgen Astellas Biopharma’s osteoporosis medicine Evenity (romosozumab)…

To read the full story

Related Article

REGULATORY

By Yasuchika Hisatani

In early October, the Japanese Heart Failure Society (JHFS) held its first annual scientific meeting since it published a focused update of the heart failure treatment guidelines in March jointly with the Japanese Circulation Society. The confab featured a series…

By Philip Carrigan

If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…